09 February 2015
EMA/PRAC/92670/2015
Pharmacovigilance Risk Assessment Committee (PRAC)

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 09-12 February 2015

Chair: June Raine – Vice-Chair: Almath Spooner

09 February 2015, 13:00 – 19:00, room 3/A

10 February 2015, 08:30 – 19:00, room 3/A

11 February 2015, 08:30 – 19:00, room 3/A

12 February 2015, 08:30 – 16:00, room 3/A

Organisational, regulatory and methodological matters (ORGAM)

26 February 2015, 10:00-12:00, room 6/B, via teleconference

Health and Safety Information

In accordance with the Agency's Health and Safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. The start of referrals will also be announced in the meeting highlights. For orphan medicinal products, the applicant name is published as this information is already publicly available.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they relate to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

Table of contents

1. Introduction 10
1.1. Welcome and declarations of interest of members, alternates and experts 10
1.2. Adoption of agenda of the meeting of 09-12 February 2015 10
1.3. Minutes of the previous PRAC meeting on 06-09 January 2015 10
2. EU Referral Procedures for Safety Reasons: Urgent EU Procedures 10
2.1. Newly triggered procedures 10
2.2. Ongoing procedures 10
2.3. Procedures for finalisation 10
2.4. Planned public hearings 10
3. EU Referral Procedures for Safety Reasons: Other EU Referral Procedures 10
3.1. Newly triggered procedures 10
3.2. Ongoing procedures 10
3.3. Procedures for finalisation 11
3.3.1. Codeine (NAP) 11
3.3.2. Hydroxyzine (NAP) 11
3.4. Article 5(3) of Regulation (EC) No 726/2004 as amended: PRAC advice on CHMP request 11
3.5. Others 11
4. Signals assessment and prioritisation 12
4.1. New signals detected from EU spontaneous reporting systems 12
4.1.1. Aliskiren – RASILAMLO (CAP), RASILEZ (CAP), RASILEZ HCT (CAP) 12
4.1.2. Everolimus – AFINITOR (CAP), VOTUBIA (CAP), NAP 12
4.1.3. Teriparatide – FORSTEO (CAP) 12
4.2. New signals detected from other sources 13
4.3. Signals follow-up and prioritisation 13
4.3.1. Amiodarone (NAP) 13
4.3.2. Aripiprazole – ABILIFY (CAP), ABILIFY MAINTENA (CAP) 13
4.3.3. Paliperidone – INVEGA (CAP) 13
4.3.4. Sodium containing formulations of effervescent, dispersible and soluble medicines (NAP) 13
5. Risk Management Plans 14
5.1. Medicines in the pre-authorisation phase 14
5.1.1. Aripiprazole 14
5.1.2. Aripiprazole 14
5.1.3. Betulae cortex dry extract 14
5.1.4. Blinatumomab 14
5.1.5. Ceritinib 15
5.1.6. Edoxaban 15
5.1.7. Efmoroctocog alfa 15
5.1.8. Human fibrinogen, human thrombin 15
5.1.9. Idebenone 16

5.1.10. Lutetium, isotope of mass 177 16
5.1.11. Pegfilgrastim 16
5.1.12. Pemetrexed 16
5.1.13. Pemetrexed 16
5.1.14. Pemetrexed 17
5.1.15. Pemetrexed 17
5.1.16. Pregabalin 17
5.1.17. Pregabalin 17
5.1.18. Tasimelteon 18
5.1.19. Tolvaptan 18
5.2. Medicines already authorised 18
RMP in the context of a variation – PRAC-led procedure 18
5.2.1. Alglucosidase alfa – MYOZYME (CAP) 18
5.2.2. Crizotinib – XALKORI (CAP) 18
5.2.3. Memantine – AXURA (CAP), EBIXA (CAP), MEMANTINE MERZ (CP) 19
5.2.4. Pegfilgrastim – NEULASTA (CAP) 19
5.2.5. Tenofovir disoproxil – VIREAD (CAP) Tenofovir disoproxil, emtricitabine – EVIPLERA (CAP), TRUVADA (CAP) 19
5.2.6. Tocilizumab – ROACTEMRA (CAP) 20
5.2.7. Vildagliptin – GALVUS (CAP), JALRA (CAP), XILIARX (CAP) vildagliptin, metformin – EUCREAS (CAP), ICANDRA (CAP), ZOMARIST (CAP) 20
RMP in the context of a variation – CHMP-led procedure 20
5.2.8. Adalimumab – HUMIRA (CAP) 20
5.2.9. Adalimumab – HUMIRA (CAP) 21
5.2.10. Ambrisentan – VOLIBRIS (CAP) 21
5.2.11. Bevacizumab – AVASTIN (CAP) 21
5.2.12. Bevacizumab – AVASTIN (CAP) 22
5.2.13. Caffeine – PEYONA (CAP) 22
5.2.14. Darbepoetin alfa – ARANESP (CAP) 22
5.2.15. Deferiprone – FERRIPROX (CAP) 23
5.2.16. Dimethyl fumarate – TECFIDERA (CAP) 23
5.2.17. Efavirenz – SUSTIVA (CAP) 23
5.2.18. Eltrombopag – REVOLADE (CAP) 24
5.2.19. Empagliflozin – JARDIANCE (CAP) 24
5.2.20. Enzalutamide – XTANDI (CAP) 24
5.2.21. Fentanyl – INSTANYL (CAP) 25
5.2.22. Febuxostat – ADENURIC (CAP) 25
5.2.23. Golimumab – SIMPONI (CAP) 25
5.2.24. Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) – CERVARIX (CAP) 26
5.2.25. Ibrutinib – IMBRUVICA (CAP) 26
5.2.26. Insulin glargine – OPTISULIN (CAP) 26
5.2.27. Ivacaftor – KALYDECO (CAP) 27
5.2.28. Ivacaftor – KALYDECO (CAP) 27
5.2.29. Ivacaftor – KALYDECO (CAP) 27
5.2.30. Lomitapide – LOJUXTA (CAP) 28

5.2.31. Nintedanib – VARGATEF (CAP) 28
5.2.32. Ocriplasmin – JETREA (CAP) 28
5.2.33. Ofatumumab – ARZERRA (CAP) 29
5.2.34. Pegvisomant – SOMAVERT (CAP) 29
5.2.35. Ponatinib – ICLUSIG (CAP) 29
5.2.36. Pyronaridine phosphate, artesunate – PYRAMAX (Art 58) 29
5.2.37. Riociguat – ADEMPAS (CAP) 30
5.2.38. Rivaroxaban – XARELTO (CAP) 30
5.2.39. Romiplostim – NPLATE (CAP) 30
5.2.40. Silodosin – SILODYX (CAP), UROREC (CAP) 31
5.2.41. Telaprevir – INCIVO (CAP) 31
5.2.42. Trastuzumab – HERCEPTIN (CAP) 31
5.2.43. Ulipristal – ESMYA (CAP) 32
RMP evaluated in the context of a PSUR procedure 32
RMP evaluated in the context of PASS results 32
RMP evaluated in the context of a five-year renewal of the marketing authorisation 32
5.2.44. Alendronic acid, colecalciferol – FOSAVANCE (CAP) 32
RMP evaluated in the context of a stand-alone RMP procedure 32
Others 33
6. Periodic Safety Update Reports (PSURs) 33
6.1. Evaluation of PSUR procedures 33
6.1.1. Aclidinium bromide – BRETARIS GENUAIR (CAP), EKLIRA GENUAIR (CAP) 33
6.1.2. Aflibercept – ZALTRAP (CAP) 33
6.1.3. Agalsidase alfa – REPLAGAL (CAP) 33
6.1.4. Aripiprazole – ABILIFY (CAP), ABILIFY MAINTENA (CAP) 34
6.1.5. Asenapine – SYCREST (CAP) 34
6.1.6. Axitinib – INLYTA (CAP) 34
6.1.7. Botulinum toxin type B – NEUROBLOC (CAP) 34
6.1.8. Catridecacog – NOVOTHIRTEEN (CAP) 35
6.1.9. Colistimethate sodium – COLOBREATHE (CAP) 35
6.1.10. Collagenase clostridium histolyticum – XIAPEX (CAP) 35
6.1.11. Copper (^{64}Cu) chloride – CUPRYMINA (CAP) 35
6.1.12. Corifollitropin alfa – ELONVA (CAP) 36
6.1.13. Dapagliflozin, metformin – XIGDUO (CAP) 36
6.1.14. Diphtheria (D), tetanus (T), pertussis (whole cell) (PW) and hepatitis b (rDNA) (HBV) vaccine (adsorbed) – TRITANRIX HB (Art 58) 36
6.1.15. Dolutegravir – TIVICAY (CAP) 37
6.1.16. Dronedarone – MULTAQ (CAP) 37
6.1.17. Emtricitabine, rilpivirine, tenofovir disoproxil – EVIPLERA (CAP) 37
6.1.18. Fampridine – FAMPYRA (CAP) 37
6.1.19. Gefitinib – IRESSA (CAP) 38
6.1.20. Idursulfase – ELAPRASE (CAP) 38
6.1.21. Infliximab – INFLECTRA (CAP), REMSIMA (CAP) 38
6.1.22. Ingenol mebutate – PICATO (CAP) 38
6.1.23. Ivacaftor – KALYDECO (CAP) 39

6.1.24. Lipegfilgrastim – LONQUEX (CAP) 39
6.1.25. Lixisenatide – LYXUMIA (CAP) 39
6.1.26. Lomitapide – LOJUXTA (CAP) 39
6.1.27. Meningococcal group B vaccine (rDNA, component, adsorbed) – BEXSERO (CAP) ..40
6.1.28. Methoxy polyethylene glycol-epoetin beta – MIRCERA (CAP) 40
6.1.29. Modified vaccinia Ankara virus – IMVANEX (CAP) 40
6.1.30. Nitric oxide – INOMAX (CAP), NAP 41
6.1.31. Palivizumab – SYNAGIS (CAP) 41
6.1.32. Pegloticase – KRYSTEXXA (CAP) 41
6.1.33. Perampanel – FYCOMPA (CAP) 41
6.1.34. Ribavirin – REBETOL (CAP), RIBAVIRIN MYLAN (CAP), RIBAVIRIN TEVA (CAP), RIBAVIRIN TEVA PHARMA BV (CAP), NAP 42
6.1.35. Romiplostim – NPLATE (CAP) 42
6.1.36. Rotavirus vaccine (live, oral) – ROTARIX (CAP) 42
6.1.37. Saxagliptin – ONGLYZA (CAP) 42
6.1.38. Stavudine – ZERIT (CAP) 43
6.1.39. Tocofersolan – VEDROP (CAP) 43
6.1.40. Vismodegib – ERIVEDGE (CAP) 43
6.2. Follow-up to PSUR procedures 44
6.2.1. Agomelatine – THYMANAX (CAP), VALDOXAN (CAP) 44
6.2.2. Epoetin beta – NEORECORMON (CAP) 44
6.2.3. Vernakalant – BRINAVESS (CAP) 44
7. Post-authorisation Safety Studies (PASS) 45
7.1. Protocols of PASS imposed in the marketing authorisation(s) 45
7.1.1. Hydroxyethyl starch (HES) (NAP) 45
7.1.2. Teicoplanin (NAP) 45
7.2. Protocols of PASS non-imposed in the marketing authorisation(s) 45
7.2.1. Aflibercept – ZALTRAP (CAP) 45
7.2.2. Aripiprazole – ABILIFY MAINTENA (CAP) 46
7.2.3. Delamanid – DELTYBA (CAP) 46
7.2.4. Flutemetamol (^{18}F)– VIZAMYL (CAP) 46
7.2.5. Flutemetamol (^{18}F) – VIZAMYL (CAP) 47
7.2.6. Follitropin alfa – OVALEAP (CAP) 47
7.2.7. Ipilimumab – YERVOY (CAP) 47
7.2.8. Mixture of polynuclear iron(III)-oxyhydroxide , sucrose and starches – VELPHORO (CAP) 48
7.2.9. Nilotinib – TASIGNA (CAP) 48
7.2.10. Tocilizumab – ROACTEMRA (CAP) 48
7.3. Results of PASS imposed in the marketing authorisation(s) 48
7.4. Results of PASS non-imposed in the marketing authorisation(s) 49
7.4.1. Aliskiren – RASILEZ (CAP) aliskiren, amlodipine – RASILAMLO (CAP) aliskiren, hydrochlorothiazide - RASILEZ HCT (CAP) 49
7.4.2. Bivalirudin – ANGIOX (CAP) 49
7.4.3. Elvitegravir – VITEKTA (CAP) 49
7.4.4. Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil – STRIBILD (CAP) 50

7.4.5. Etanercept – ENBREL (CAP) 50
7.4.6. Etanercept – ENBREL (CAP) 50
7.4.7. Ivacaftor – KALYDECO (CAP) 51
7.4.8. Lamivudine, zidovudine – COMBIVIR (CAP) 51
7.4.9. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) – PREVENAR 13 (CAP) 51
7.4.10. Tolvaptan – SAMSCA (CAP) 51
7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variations regulation 52
7.5.1. Efavirenz – SUSTIVA (CAP) 52
7.5.2. Efavirenz, emtricitabine, tenofovir disoproxil – ATRIPLA (CAP) 52
7.5.3. Emtricitabine, tenofovir disoproxil – TRUVADA (CAP) 52
7.5.4. Filgrastim – BIOGRASTIM (CAP), RATIOGRASTIM (CAP), TEVAGRASTIM (CAP) 53
7.5.5. Infliximab – INFLECTRA (CAP) 53
7.5.6. Influenza vaccine (split viron, inactivated) – IDFLU (CAP), INTANZA (CAP) 53
7.5.7. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) – OPTAFLU (CAP) 54
7.5.8. Mannitol – BRONCHITOL (CAP) 54
7.5.9. Oseltamivir – TAMIFLU (CAP) 54
7.5.10. Raltegravir – ISENTRESS (CAP) 55
7.5.11. Tenofovir disoproxil – VIREAD (CAP) 55
7.5.12. Ticagrelor – BRILIQUE (CAP) 55

8. Renewals of the marketing authorisation, conditional renewals and annual reassessments 56

8.1.1. Anagrelide – XAGRID (CAP) 56
8.1.2. Histamine dihydrochloride – CEPLENE (CAP) 56
8.1.3. Trabectedin – YONDELIS (CAP) 56

9. Product related pharmacovigilance inspections 56

9.1. List of planned pharmacovigilance inspections 56
9.2. On-going or concluded pharmacovigilance inspections 57
9.3. Others 57

10. Other safety issues for discussion requested by the CHMP or the EMA 57

10.1. Safety related variations of the marketing authorisation (MA) 57
10.1.1. Albiglutide – EPERZAN (CAP) 57
10.1.2. Ambrisentan – VOLIBRIS (CAP) 57
10.2. Timing and message content in relation to MS safety announcements 58
10.3. Other requests 58
10.3.1. Dabigatran – PRADAXA (CAP) 58
10.3.2. Epoetins: Darbepoetin alfa – ARANESP (CAP); Epoetin alfa – ABSEAMED (CAP), BINOCRIT (CAP), EPOETIN ALFA HEXAL (CAP); Epoetin beta – MIRCERA (CAP), NEORECORMON (CAP); Epoetin theta – BIOPOIN (CAP), EPORATIO (CAP); Epoetin zeta – RETACRIT (CAP), SILAPO (CAP) 58

11. Other safety issues for discussion requested by the Member States ... 59

11.1. Safety related variations of the marketing authorisation 59
11.2. Renewals of the marketing authorisation 59

11.3. Other requests 59
12. Organisational, regulatory and methodological matters 59
12.1. Mandate and organisation of the PRAC 59
12.2. Pharmacovigilance audits and inspections 59
12.2.1. Pharmacovigilance Systems and their Quality Systems 59
12.2.2. Pharmacovigilance inspections 59
12.2.3. Pharmacovigilance audits 59
12.3. Periodic Safety Update Reports & Union Reference Date (EURD) List 59
12.3.1. Periodic Safety Update Reports 59
12.3.2. PSURs repository 59
12.3.3. Union Reference Date List 60
12.4. Signal Management 60
12.4.1. Signal Management 60
12.5. Adverse Drug Reactions reporting and additional monitoring 60
12.5.1. Management and reporting of adverse reactions to medicinal products 60
12.5.2. Additional monitoring 60
12.6. EudraVigilance database 61
12.6.1. Activities related to the confirmation of full functionality 61
12.7. Risk Management Plans and effectiveness of risk minimisations 61
12.7.1. Risk Management Systems 61
12.7.2. Tools, Educational Materials and effectiveness measurement for risk minimisations 61
12.8. Post-authorisation Safety Studies 61
12.8.1. Post-authorisation Safety Studies 61
12.9. Community procedures 61
12.9.1. Referral procedures for safety reasons 61
12.10. Renewals, conditional renewals, annual reassessments 61
12.11. Risk communication and transparency 61
12.11.1. Public participation in pharmacovigilance 61
12.11.2. Safety communication 61
12.12. Continuous pharmacovigilance 61
12.12.1. Incident Management 61
12.13. Interaction with EMA Committees and Working Parties 62
12.13.1. Committees 62
12.13.2. Blood Products Working Party (BPWP) 62
12.13.3. Vaccine Working Party (VWP) 62
12.13.4. Scientific Advisory Group (SAG) Oncology 62
12.14. Interaction within the EU regulatory network 62
12.15. Contacts of the PRAC with external parties and interaction of the EMA with interested parties 62
12.15.1. Guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 62
12.15.2. International Society for Pharmaceutical Engineering (ISPE) 62
13. Any other business 62
13.1. Medication errors 62
13.2. Pharmacovigilance programme and revised implementation governance 63

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda of the meeting of 09-12 February 2015

Status: *for adoption*

Document: PRAC Agenda Rev.3 due for publication on 06 February 2015

1.3. Minutes of the previous PRAC meeting on 06-09 January 2015

Status: *for adoption*

Document: PRAC final Minutes due for publication by 20 February 2015

2. EU Referral Procedures for Safety Reasons: Urgent EU Procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

2.4. Planned public hearings

None

3. EU Referral Procedures for Safety Reasons: Other EU Referral Procedures

3.1. Newly triggered procedures

None

3.2. Ongoing procedures

None

3.3. Procedures for finalisation

3.3.1. **Codeine** (NAP)

- Review of the benefit-risk balance of codeine indicated for the treatment of cough in paediatric patients following the notification by Germany of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Status: *for discussion and agreement of a recommendation to CMD(h)*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)
PRAC Co-Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number: EMEA/H/A-31/1394
MAH(s): various
Documents:
For adoption: PRAC AR, PRAC recommendation (or list of outstanding issues (LoOI), revised procedure timetable)
For discussion: PDCO report
For discussion: Healthcare Professionals Organisations (HCPO)' feedback

3.3.2. **Hydroxyzine** (NAP)

- Review of the benefit-risk balance of hydroxyzine following the notification by Hungary of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Status: *for discussion and agreement of a recommendation to CMD(h)*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)
PRAC Co-Rapporteur: Julia Pallos (HU)

Administrative details:
Procedure number: EMEA/H/A-31/1400
MAH(s): UCB, various
Documents:
For adoption: PRAC AR, PRAC recommendation (or list of outstanding issues (LoOI), revised procedure timetable)
For discussion: EMA Geriatric Expert Group (GEG) report

3.4. Article 5(3) of Regulation (EC) No 726/2004 as amended: PRAC advice on CHMP request

None

3.5. Others

None

4. Signals assessment and prioritisation[1]

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Aliskiren – **RASILAMLO** (CAP), **RASILEZ** (CAP), **RASILEZ HCT** (CAP)

- Signal of severe hyponatraemia leading to neurological symptoms

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Carmela Macchiarulo (IT)
Administrative details:
EPITT 18212 – New signal
MAH(s): Novartis Europharm Ltd
Lead MS: IT
Documents:
For adoption: PRAC recommendation

4.1.2. Everolimus – **AFINITOR** (CAP), **VOTUBIA** (CAP), NAP

- Signal of lymphoedema

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

Administrative details:
EPITT 18197 – New signal
MAH(s): Novartis Europharm Ltd, various
Lead MS: DE
Documents:
For adoption: PRAC recommendation

4.1.3. Teriparatide – **FORSTEO** (CAP)

- Signal of angina pectoris

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
EPITT 18203 – New signal
MAH(s): Eli Lilly Nederland B.V.
Lead MS: UK
Documents:
For adoption: PRAC recommendation

[1] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

4.2. New signals detected from other sources

None

4.3. Signals follow-up and prioritisation

4.3.1. **Amiodarone** (NAP)

- Signal of syndrome of inappropriate antidiuretic hormone (SIADH)

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
EPITT 18091 – Follow-up October 2014
MAH(s): various
Documents:
For adoption: PRAC recommendation

4.3.2. **Aripiprazole – ABILIFY** (CAP), **ABILIFY MAINTENA** (CAP)

- Signal of hyperprolactinaemia

Status*: for discussion*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

Administrative details:
EPITT 18086 – Follow-up October 2014
MAH(s): Otsuka Pharmaceutical Europe Ltd
Documents:
For adoption: PRAC recommendation

4.3.3. **Paliperidone – INVEGA** (CAP)

- Signal of accidental exposure of children to oral formulations

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
EPITT 18069 – Follow-up September 2014
MAH(s): Janssen-Cilag International N.V.
Documents:
For adoption: PRAC recommendation

4.3.4. **Sodium containing formulations of effervescent, dispersible and soluble medicines** (NAP)

- Signal of cardiovascular events

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
EPITT 17931 – Follow-up October 2014
MAH: various
Documents:
For adoption: PRAC recommendation

5. Risk Management Plans

5.1. Medicines in the pre-authorisation phase

5.1.1. Aripiprazole

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003803, *Generic*
Intended indication(s): Treatment of schizophrenia and prevention of manic episodes in bipolar I disorder
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.2. Aripiprazole

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003899, *Generic*
Intended indication(s): Treatment of schizophrenia and prevention of manic episodes in bipolar I disorder
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.3. Betulae cortex dry extract

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003938
Intended indication(s): Treatment of partial thickness wounds
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.4. Blinatumomab

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003731, *Orphan*
Intended indication(s): Treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia
Applicant: Amgen Europe B.V.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.5. Ceritinib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003819
Intended indication(s): Treatment of non-small cell lung cancer (NSCLC)
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.6. Edoxaban

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002629
Intended indication(s): Prevention of stroke, embolism and treatment of venous thromboembolism
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.7. Efmoroctocog alfa

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003964, *Orphan*
Intended indication(s): Treatment of haemophilia A
Applicant: Biogen Idec Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.8. Human fibrinogen, human thrombin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003914
Intended indication(s): Supportive treatment for improvement of haemostasis and as a suture support in vascular surgery
Documents:

For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.9. Idebenone

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003834, *Orphan*
Intended indication(s): Treatment of Leber's hereditary optic neuropathy (LHON)
Applicant: Santhera Pharmaceuticals (Deutschland) GmbH
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.10. Lutetium, isotope of mass 177

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002749
Intended indication(s): Radiolabelling of carrier molecules
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.11. Pegfilgrastim

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003910
Intended indication(s): Treatment of neutropenia
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.12. Pemetrexed

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003788, *Generic*
Intended indication(s): Treatment of malignant pleural mesothelioma and non-small cell lung cancer
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.13. Pemetrexed

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003970, *Generic*
Intended indication(s): Treatment of malignant pleural mesothelioma and non-small cell lung cancer
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.14. Pemetrexed

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003905, *Generic*
Intended indication(s): Treatment of malignant pleural mesothelioma and non-small cell lung cancer
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.15. Pemetrexed

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/004011, *Generic*
Intended indication(s): Treatment of malignant pleural mesothelioma and non-small cell lung cancer
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.16. Pregabalin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003962
Intended indication(s): Treatment of neuropathic pain, epilepsy and generalised anxiety disorder (GAD)
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.17. Pregabalin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/004078
Intended indication(s): Treatment of neuropathic pain, epilepsy and generalised anxiety disorder (GAD)
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.18. Tasimelteon

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003870, *Orphan*
Intended indication(s): Treatment of non-24-hour sleep-wake disorder (non-24)
Applicant: Vanda Pharmaceuticals Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.1.19. Tolvaptan

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002788, *Orphan*
Intended indication(s): Treatment of autosomal dominant polycystic kidney disease (ADPKD)
Applicant: Otsuka Pharmaceutical Europe Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2. Medicines already authorised

RMP in the context of a variation[2] – PRAC-led procedure

5.2.1. Alglucosidase alfa – MYOZYME (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000636/II/0052
Procedure scope: Revised RMP (version 7.2) to update the physician guide: safety information packet (version 8.1) following the conclusion of PSUV/0049 procedure in May 2014
MAH(s): Genzyme Europe BV
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.2. Crizotinib – XALKORI (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

[2] In line with the revised variation regulation for submissions as of 4 August 2013

Administrative details:
Procedure number(s): EMEA/H/C/002489/II/0025/G
Procedure scope: Grouped variations of a type II and a type IB variation: submission of a revised RMP (version 6.0) to change the CYP3A inhibitor from ketoconazole to itraconazole in study A8081001; and to change the due date for completion of MEA 009
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC AR

5.2.3. Memantine – **AXURA** (CAP), **EBIXA** (CAP), **MEMANTINE MERZ** (CP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000378/WS0668/0067, EMEA/H/C/000463/WS0668/0083, EMEA/H/C/002711/WS0668/0004
Procedure scope: Revised RMP (version 7.1) to include the interim results of the prostate cancer study, 4 finalised studies. In addition, this RMP update also introduces changes to the required additional pharmacovigilance activity regarding the identified potential risk of prostate cancer by adjusting the due dates of agreed milestones
MAH(s): Merz Pharmaceuticals GmbH (Axura, Memantine Merz), H. Lundbeck A/S (Ebixa)
Documents:
For adoption: PRAC AR

5.2.4. Pegfilgrastim – **NEULASTA** (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000420/II/0082
Procedure scope: Revised RMP (version 3) to address the PRAC recommendation concerning capillary leak syndrome and cytokine release syndrome
MAH(s): Amgen Europe B.V.
Documents:
For adoption: PRAC AR

5.2.5. Tenofovir disoproxil – **VIREAD** (CAP)
Tenofovir disoproxil, emtricitabine – EVIPLERA (CAP), **TRUVADA** (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000419/WS0598/0141/G, EMEA/H/C/002312/WS0598/0048/G, EMEA/H/C/000594/WS0598/0107/G
Procedure scope: Worksharing variation to: 1) update the RMP to remove study 174-0127 on renal safety; add references to studies previously submitted, add intermediate results for APR and MITOC studies and correct the classification from category 3 to 4 of the 7 studies (in the RMP for Eviplera and Truvada); 2) update the deadline for the final submission of study 104-0423 in the RMP
MAH(s): Gilead Sciences International Ltd
Documents:
For adoption: PRAC AR

5.2.6. Tocilizumab – ROACTEMRA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000955/II/0046
Procedure scope: Revised RMP (version 16.3) with information from the final clinical study report (CSR) of study WA 19926 (FUNCTION)
MAH(s): Roche Registration Limited
Documents:
For adoption: PRAC AR

5.2.7. Vildagliptin – GALVUS (CAP), JALRA (CAP), XILIARX (CAP) vildagliptin, metformin – EUCREAS (CAP), ICANDRA (CAP), ZOMARIST (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000771/WS0696/0040, EMEA/H/C/001048/WS0696/0039, EMEA/H/C/001051/WS0696/0038
EMEA/H/C/000807/WS/0695, EMEA/H/C/001050/WS/0695, EMEA/H/C/001049/WS/0695
Procedure scope: Revised RMP (version 12.1) to change of the due date of the final clinical study report (CSR) for study CLAF237A2401 from 'Q4 2014' to 'Q2 2015'
MAH(s): Novartis Europharm Ltd
Documents:
For adoption: PRAC AR

RMP in the context of a variation – CHMP-led procedure

5.2.8. Adalimumab – HUMIRA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000481/II/0137
Procedure scope: Extension of indication to the paediatric population of the treatment of active moderate to severe hidradenitis suppurativa (acne inversa), including treatment of inflammatory lesions and prevention of worsening of abscesses and draining fistulas. Consequential changes to SmPC sections 4.2, 4.4, 4.8, 5.1 and 5.2 and to the package leaflet
MAH(s): AbbVie Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.9. Adalimumab – HUMIRA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000481/II/0134
Procedure scope: Extension of indication to add the treatment of chronic plaque psoriasis in children and adolescents from 4 years of age, based on data from study M04-717 'multicentre, randomised, double-dummy, double-blind study evaluating two doses of adalimumab versus methotrexate in paediatric subjects with chronic plaque psoriasis.' As a consequence SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 and the package leaflet have been updated accordingly. In addition, the MAH proposed minor editorial changes in the SmPC and package leaflet
MAH(s): AbbVie Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.10. Ambrisentan – VOLIBRIS (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000839/II/0039
Procedure scope: Update of SmPC section 4.4 in relation to the current recommendations for liver function and section 5.1 with data on aminotransferase abnormalities from an analysis of the clinical safety report (CSR) for PASS AMB110094 (VOLT). The current healthcare professional information in Annex II has been updated accordingly as well as the package leaflet and RMP (version 6)
MAH(s): Glaxo Group Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.11. Bevacizumab – AVASTIN (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000582/II/0072
Procedure scope: Extension of indication for the use of Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan in patient with persistent, recurrent, or metastatic carcinoma of the cervix. Consequently, SmPC sections 4.1, 4.2, 4.4, 4.8 and 5.1 and package leaflet are updated
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.12. Bevacizumab – AVASTIN (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Doris Stenver (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000582/II/0080
Procedure scope: Update of SmPC sections 4.6, 4.8 and 5.3 to update the safety information regarding a contraindication during pregnancy and the potential for foetal abnormalities based on post-marketing data showing that foetal malformations have been observed in children of pregnant patients treated with bevacizumab in combination with embryotoxic chemotherapeutics
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.13. Caffeine – PEYONA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Jan Neuhauser (AT)

Administrative details:
Procedure number(s): EMEA/H/C/001014/II/0013
Procedure scope: Update of SmPC section 4.8 to reflect the results of a European non-interventional post-authorisation study to assess the drug utilisation and safety of caffeine citrate in the treatment of premature infants affected by apnoea. The package leaflet is updated accordingly
MAH(s): Chiesi Farmaceutici S.p.A.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.14. Darbepoetin alfa – ARANESP (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Valerie Strassmann (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000332/II/0130

Procedure scope: Update of SmPC section 4.2 to incorporate dosing recommendations for paediatric patients from 1 to < 11 years of age and include updates to SmPC sections 4.8, 5.1 and 5.2 to reflect the available data in the paediatric population. The package leaflet is updated accordingly
MAH(s): Amgen Europe B.V.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.15. Deferiprone – FERRIPROX (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000236/II/0089/G
Procedure scope: Update of SmPC section 4.5 regarding combination of deferiprone with other iron chelators further to request of the PRAC in the assessment of the PSUR (PSUV/083). Update of SmPC section 5.1 and the RMP with the results of study LA37-111 conducted to evaluate the effect of deferiprone on cardiac QT and QTc interval duration. The package leaflet is updated accordingly
MAH(s): Apotex Europe BV
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.16. Dimethyl fumarate – TECFIDERA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/002601/WS0689/0011
Procedure scope: Update of SmPC sections 4.4 to add a recommendation to consider interruption of treatment in patients with low lymphocyte counts (<0.5 x 109/L) persisting for more than six months and to monitor lymphocyte counts until recovery. Update of SmPC section 4.8 with information on observed low lymphocyte counts in clinical studies and progressive multifocal leukoencephalopathy (PML) occurrence in the setting of severe and prolonged lymphopenia
MAH(s): Biogen Idec Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.17. Efavirenz – SUSTIVA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

Administrative details:
Procedure number(s): EMEA/H/C/000249/II/0126/G

Procedure scope: Grouped variation consisting of two consequential variations: 1) type II variation to extend the therapeutic indication to include children 3 months of age to less than 3 year of age and weighing at least 3.5kg; 2) type IB variation, consequential to this update, to remove the oral solution pharmaceutical form for Sustiva (efavirenz) and as such upgrade the already approved 'capsule sprinkle' dosing method as primary means of dosing for young patients and those that cannot swallow capsules and/or tablets
MAH(s): Bristol-Myers Squibb Pharma EEIG
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.18. Eltrombopag – REVOLADE (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/001110/II/0020
Procedure scope: Update of SmPC sections 4.1, 4.2, 4.4, 4.8 and 5.1 to add a new indication on the treatment of adult patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy. The package leaflet is updated accordingly
MAH(s): GlaxoSmithKline Trading Services
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.19. Empagliflozin – JARDIANCE (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Miguel Angel Macia (ES)

Administrative details:
Procedure number(s): EMEA/H/C/002677/II/0005 (with RMP)
Procedure scope: Submission of an updated environmental risk assessment (ERA) and final study report for a toxicity study on a sediment dwelling organism (OECD 218) performed as a post-approval measure
MAH(s): Boehringer Ingelheim International GmbH
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.20. Enzalutamide – XTANDI (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/002639/II/0015

Procedure scope: Update of SmPC sections 4.2, 4.4 and 5.2 to update the safety and pharmacokinetic information on hepatic impairment after finalisation of the study 9785-CL-0404. The package leaflet is updated accordingly
MAH(s): Astellas Pharma Europe B.V.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.21. Fentanyl – INSTANYL (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000959/X/0030G
Procedure scope: Grouped variation including the 1) addition of a new strength of 400 micrograms/dose in a multi-dose nasal spray in pack size of 10, 20, 30 and 40 doses; 2) replacement of the current multi-dose nasal spray by a new improved child resistant multi-dose nasal spray; 3) addition of a new pack size of 30 doses for each current strength (50 micrograms/dose, 100 micrograms/dose & 200 micrograms/dose); 4) tightening of the assay release limit of the multi-dose finished product to 98.0%-102.0%; 5) reduction of the shelf life of all strengths of the multi-dose finished product to 24 months
MAH(s): Takeda Pharma A/S
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.22. Febuxostat – ADENURIC (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Jan Neuhauser (AT)

Administrative details:
Procedure number(s): EMEA/H/C/000777/II/0037
Procedure scope: Update of SmPC sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 for the 120 mg strength further to the introduction of a new indication for prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumour lysis syndrome (TLS). The package leaflet is updated accordingly
MAH(s): Menarini International Operations Luxembourg S.A.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.23. Golimumab – SIMPONI (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000992/II/0061
Procedure scope: Update of SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of to add a new therapeutic indication for non-radiographic axial spondyloarthritis. The package leaflet is updated accordingly
MAH(s): Janssen Biologics B.V.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.24. Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) – CERVARIX (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Jean-Michel Dogné (BE)

Administrative details:
Procedure number(s): EMEA/H/C/000721/II/0061
Procedure scope: Update of SmPC section 4.6 on pregnancy outcomes in women exposed to the vaccine during pregnancy to reflect the outcome of study EPI-HPV-018 (an observational cohort) and other available data on safety during pregnancy. The package leaflet is amended accordingly
MAH(s): GlaxoSmithKline Biologicals
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.25. Ibrutinib – IMBRUVICA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/003791/II/0001
Procedure scope: Extension of indication to the treatment of adult patients with Waldenström macroglobulinaemia (WM). Consequently, changes are proposed to SmPC sections 4.1, 4.2, 4.8 and 5.1 and to the package leaflet to incorporate all information relevant to the WM indication
MAH(s): Janssen-Cilag International NV
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.26. Insulin glargine – OPTISULIN (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/000309/X/0079/G
Procedure scope: Extension of the MA of Optisulin to register additional strength 300 U/ml, grouped with type IA variation to vary the invented name from Optisulin to Toujeo

MAH(s): Sanofi-aventis Deutschland GmbH
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.27. Ivacaftor – KALYDECO (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

Administrative details:
Procedure number(s): EMEA/H/C/002494/II/0027
Procedure scope: Extension of indication to include the treatment of cystic fibrosis in patients aged 18 years and older who have a R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Consequently, SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 and the package leaflet are updated
MAH(s): Vertex Pharmaceuticals (U.K.) Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.28. Ivacaftor – KALYDECO (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

Administrative details:
Procedure number(s): EMEA/H/C/002494/II/0031
Procedure scope: Update of SmPC sections 4.8 and 5.1 to reflect the results of part 2 of study VX12-770-111 as fulfilment of the post-authorisation measure (PAM) MEA 007
MAH(s): Vertex Pharmaceuticals (U.K.) Ltd.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.29. Ivacaftor – KALYDECO (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

Administrative details:
Procedure number(s): EMEA/H/C/002494/X/0034/G
Procedure scope: Line extension for a new pharmaceutical form in two strengths (50 mg and 75 mg unit doses) to support an indication extension of Kalydeco to treat cystic fibrosis (CF) patients aged 2 to less than 6 years old. A type II variation has been submitted together to align the SmPC with the new data is grouped with the extension application
MAH(s): Vertex Pharmaceuticals (U.K.) Ltd.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.30. Lomitapide – LOJUXTA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002578/II/0014/G
Procedure scope: Grouping of three type II variations: 1) submission of the clinical study report (CSR) for study AEGR-733-024 undertaken to investigate the effect of atorvastatin (a weak CYP3A4 inhibitor) on the pharmacokinetics of lomitapide.; 2) submission of the CSR for study AEGR-733-029 undertaken to investigate the effect of ethinyl estradiol/norgestimate (weak CYP3A4 inhibitor) on the pharmacokinetics of lomitapide; 3) submission of the final report related to the validation of a mechanistic (PBPK) model to predict lomitapide interactions with CYP3A4 inhibitors. As a consequence SmPC sections 4.2, 4.4 and 4.5,the package leaflet and the RMP are updated accordingly
MAH(s): Aegerion Pharmaceuticals Limited
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.31. Nintedanib – VARGATEF (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Leonidas Klironomos (GR)

Administrative details:
Procedure number(s): EMEA/H/C/002569/II/0001
Procedure scope: Submission of the final clinical trial report for study PK140T (in vitro evaluation of the interaction of nintedanib with human OAT transporters) in order to fulfil a post-authorisation measure (MEA) included as additional activity in the RMP
MAH(s): Boehringer Ingelheim International GmbH
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.32. Ocriplasmin – JETREA (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C002381/X/0013
Procedure scope: Introduction of a ready-to-use (RTU) formulation with adjusted fill volume for Jetrea 0.375 mg/0.3 mL
MAH(s): ThromboGenics NV
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.33. Ofatumumab – ARZERRA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

Administrative details:
Procedure number(s): EMEA/H/C/001131/II/0035
Procedure scope: Submission of a study investigating the safety and efficacy of ofatumumab therapy versus physicians' choice in patients with bulky fludarabine refractory chronic lymphocytic leukemia (CLL) to address the outstanding specific obligation of the conditional MA. As a consequence the MAH proposes to change the status of the MA from conditional to a full MA. The product information and RMP are updated accordingly
MAH(s): Glaxo Group Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.34. Pegvisomant – SOMAVERT (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000409/X/0072
Procedure scope: Addition of 25 mg and 30 mg powder and solvent for solution for injection
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.35. Ponatinib – ICLUSIG (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002695/II/0017
Procedure scope: Update of SmPC sections 4.8 and 5.1 to update the safety information and to update pharmacology information after the availability of the updated Clinical Study report for Study AP24534-10-201 (PACE). The RMP is updated accordingly. The MAH take this opportunity to update the RMP as for the requests received during the referral procedure (EMEA/H/C/002695/A-20/0003)
MAH(s): Ariad Pharma Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.36. Pyronaridine phosphate, artesunate – PYRAMAX (Art 58)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/W/002319/X/0008/G
Procedure scope: Line extension to add a new paediatric formulation:60 mg/20 mg granules for oral suspension. The product information for Pyramax 180 mg/60 mg film coated tablets is updated accordingly
MAH(s): Shin Poong Pharmaceutical Co., Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.37. Riociguat – ADEMPAS (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002737/II/0006
Procedure scope: Submission of category 3 in vitro study to determine the substrate characteristics of riociguat and metabolite M-1 towards human transporters
MAH(s): Bayer Pharma AG
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.38. Rivaroxaban – XARELTO (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000944/II/0034
Procedure scope: Amendment of the Annex II of the marketing authorisation: as an alternative to the study imposed as specific obligation, the company proposes to extend and expand the ongoing epidemiological rivaroxaban PASS programme to fulfil the CHMP objective on the post approval programme for the acute coronary syndrome (ACS) indication
MAH(s): Bayer Pharma AG
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.39. Romiplostim – NPLATE (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000942/II/0049
Procedure scope: Update of SmPC sections 4.8 and 5.1 based on the final clinical study report (CSR) for study 20080009: a long-term open-label prospective study to assess changes in bone marrow morphology
MAH(s): Amgen Europe B.V.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.40. Silodosin – **SILODYX** (CAP), **UROREC** (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001209/WS0672/G, EMEA/H/C/001092/WS0672/G
Procedure scope: Grouping of two variations: 1) Update of SmPC sections 4.8 and 5.1 to add efficacy and safety information from a European phase IV open label clinical study undertaken in patients with benign prostate hyperplasia; 2) update of the RMP with changes requested by the PRAC in the recent renewal and PSUR procedures.
MAH(s): Recordati Ireland Ltd.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.41. Telaprevir – **INCIVO** (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002313/II/0035
Procedure scope: As part of the RMP commitments to address the missing information in the liver post-transplant population and based on the submission the phase 3b study report HPC3006, update of SmPC section 4.2 to provide posology information for the special population of liver transplant patients without cirrhosis and of section 4.4 to add a warning for organ transplant patients. SmPC section 4.5, 4.8 and 5.1 are also updated to reflect the new safety and clinical data of the study. The package leaflet is updated accordingly
MAH(s): Janssen-Cilag International N.V.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.42. Trastuzumab – **HERCEPTIN** (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000278/II/0084/G
Procedure scope: Update of SmPC sections 4.2 and 4.8 with information on switching between intravenous (IV) and subcutaneous (SC) formulations further to safety data from study MO22982. The package leaflet is updated accordingly. Update of SmPC section 4.2 with a statement regarding switching between Herceptin and biosimilars
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

5.2.43. Ulipristal – ESMYA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002041/II/0028
Procedure scope: Update of SmPC section 4.1 with subsequent updates to sections 4.2, 4.4, 4.8 and 5.1 in order to extend the current indication to long term (repeated intermittent) treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The package leaflet is updated accordingly
MAH(s): Gedeon Richter Plc.
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

RMP evaluated in the context of a PSUR procedure

None

RMP evaluated in the context of PASS results

See also Elvitegravir – VITEKTA 7.4.3. , Ivacaftor – KALYDECO 7.4.7. , Lamivudine, zidovudine – COMBIVIR 7.4.8.

RMP evaluated in the context of a five-year renewal of the marketing authorisation

5.2.44. Alendronic acid, colecalciferol – FOSAVANCE (CAP)

- Evaluation of an RMP on the context of a five year-renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000619/R/0032 (with RMP)
MAH(s): Merck Sharp & Dohme Limited
Documents:
For adoption: PRAC RMP AR, PRAC RMP assessment overview and advice

RMP evaluated in the context of a stand-alone RMP procedure

None

Others

Bisphosphonates, denosumab and risk of osteonecrosis of the jaw (ONJ): consultation with Scientific Advisory Group (SAG) Oncology and action plan for implementation, see under 12.13.4.

6. Periodic Safety Update Reports (PSURs)

6.1. Evaluation of PSUR procedures[3]

6.1.1. Aclidinium bromide – **BRETARIS GENUAIR** (CAP), **EKLIRA GENUAIR** (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002706//PSUSA/09005/201407, EMEA/H/C/002211//PSUSA/09005/201407
MAH(s): Almirall S.A
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.2. Aflibercept – **ZALTRAP** (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002532//PSUSA/10019/201408
MAH(s): Sanofi-Aventis Groupe
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.3. Agalsidase alfa – **REPLAGAL** (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/000369//PSUSA/00069/201408
MAH(s): Shire Human Genetic Therapies AB

[3] Where a regulatory action is recommended (variation, suspension or revocation of the terms of Marketing Authorisation(s)), the assessment report and PRAC recommendation are transmitted to the CHMP for adoption of an opinion. Where PRAC recommends the maintenance of the terms of the marketing authorisation(s), the procedure finishes at the PRAC level

Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.4. Aripiprazole – **ABILIFY** (CAP), **ABILIFY MAINTENA** (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

Administrative details:
Procedure number(s): EMEA/H/C/000471//PSUSA/00234/201407, EMEA/H/C/002755//PSUSA/00234/201407
MAH(s): Otsuka Pharmaceutical Europe Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.5. Asenapine – **SYCREST** (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001177//PSUSA/00256/201408
MAH(s):N.V. Organon
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.6. Axitinib – **INLYTA** (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ingebjørg Buajordet (NO)

Administrative details:
Procedure number(s): EMEA/H/C/002406//PSUSA/10022/201407
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.7. Botulinum toxin type B – **NEUROBLOC** (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Magda Pedro (PT)

Administrative details:
Procedure number(s): EMEA/H/C/000301//PSUSA/00428/201406
MAH(s): Eisai Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.8. Catridecacog – NOVOTHIRTEEN (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/002284//PSUSA/10034/201407
MAH(s): Novo Nordisk A/S
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.9. Colistimethate sodium – COLOBREATHE (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001225//PSUSA/09112/201408
MAH(s): Forest Laboratories UK Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.10. Collagenase clostridium histolyticum – XIAPEX (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/002048//PSUSA/00871/201402
MAH(s): Swedish Orphan Biovitrum AB (publ)
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.11. Copper (^{64}Cu) chloride – CUPRYMINA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002136//PSUSA/10040/201408
MAH(s): Sparkle Srl
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.12. Corifollitropin alfa – ELONVA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001106//PSUSA/00875/201407
MAH(s): Merck Sharp & Dohme Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.13. Dapagliflozin, metformin – XIGDUO (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002672//PSUSA/10294/201407
MAH(s): AstraZeneca AB
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.14. Diphtheria (D), tetanus (T), pertussis (whole cell) (PW) and hepatitis b (rDNA) (HBV) vaccine (adsorbed) – TRITANRIX HB (Art 58)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

Administrative details:
Procedure number(s): EMEA/H/W/003838//PSUV/0007
MAH(s): GlaxoSmithKline Biologicals S.A.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.15. Dolutegravir – TIVICAY (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002753//PSUSA/10075/201407
MAH(s): ViiV Healthcare
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.16. Dronedarone – MULTAQ (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001043//PSUSA/01180/201407
MAH(s): sanofi-aventis groupe
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.17. Emtricitabine, rilpivirine, tenofovir disoproxil – EVIPLERA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002312//PSUSA/09142/201408
MAH(s): Gilead Sciences International Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.18. Fampridine – FAMPYRA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002097//PSUSA/01352/201407
MAH(s): Biogen Idec Ltd.

Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.19. Gefitinib – IRESSA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/001016//PSUSA/01518/201407
MAH(s): AstraZeneca AB
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.20. Idursulfase – ELAPRASE (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000700//PSUSA/01722/201407
MAH(s): Shire Human Genetic Therapies AB
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.21. Infliximab – INFLECTRA (CAP), REMSIMA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002778//PSUSA/10106/201407, EMEA/H/C/002576//PSUSA/10106/201407
MAH(s): Hospira UK Limited, Celltrion Healthcare Hungary Kft.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.22. Ingenol mebutate – PICATO (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002275//PSUSA/10035/201407
MAH(s): Leo Pharma A/S
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.23. Ivacaftor – KALYDECO (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

Administrative details:
Procedure number(s): EMEA/H/C/002494//PSUSA/09204/201407
MAH(s): Vertex Pharmaceuticals (U.K.) Ltd.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.24. Lipegfilgrastim – LONQUEX (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002556//PSUSA/10111/201407
MAH(s): Sicor Biotech UAB
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.25. Lixisenatide – LYXUMIA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002445//PSUSA/10017/201407
MAH(s): Sanofi-Aventis Groupe
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.26. Lomitapide – LOJUXTA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002578//PSUSA/10112/201407
MAH(s): Aegerion Pharmaceuticals Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.27. Meningococcal group B vaccine (rDNA, component, adsorbed) – BEXSERO (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002333//PSUSA/10043/201407
MAH(s): Novartis Vaccines and Diagnostics S.r.l.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.28. Methoxy polyethylene glycol-epoetin beta – MIRCERA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000739//PSUSA/02017/201407
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.29. Modified vaccinia Ankara virus – IMVANEX (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002596//PSUSA/10119/201407
MAH(s): Bavarian Nordic A/S
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.30. Nitric oxide – INOMAX (CAP), NAP

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000337//PSUSA/02172/201406
MAH(s): Linde Healthcare AB, various
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.31. Palivizumab – SYNAGIS (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Torbjorn Callreus (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000257//PSUSA/02267/201406
MAH(s): AbbVie Ltd.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.32. Pegloticase – KRYSTEXXA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/002208//PSUSA/10046/201407
MAH(s): Crealta Pharmaceuticals Ireland Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.33. Perampanel – FYCOMPA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002434//PSUSA/09255/201407
MAH(s): Eisai Europe Ltd.

Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.34. Ribavirin – REBETOL (CAP), **RIBAVIRIN MYLAN** (CAP), **RIBAVIRIN TEVA** (CAP), **RIBAVIRIN TEVA PHARMA BV** (CAP), NAP

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000246//PSUSA/10007/201407, EMEA/H/C/001185//PSUSA/10007/201407, EMEA/H/C/001018//PSUSA/10007/201407, EMEA/H/C/001064//PSUSA/10007/201407
MAH(s): Merck Sharp & Dohme Limited, Generics (UK) Limited, Teva B.V., various
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.35. Romiplostim – NPLATE (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000942//PSUSA/02660/201407
MAH(s): Amgen Europe B.V.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.36. Rotavirus vaccine (live, oral) – ROTARIX (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

Administrative details:
Procedure number(s): EMEA/H/C/000639//PSUSA/02665/201407
MAH(s): GlaxoSmithKline Biologicals S.A.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.37. Saxagliptin – ONGLYZA (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001039//PSUSA/02685/201407
MAH(s): AstraZeneca AB
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.38. Stavudine – ZERIT (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000110//PSUSA/02787/201406
MAH(s): Bristol-Myers Squibb Pharma EEIG
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.39. Tocofersolan – VEDROP (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000920//PSUSA/02981/201407
MAH(s): Orphan Europe S.A.R.L.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.40. Vismodegib – ERIVEDGE (CAP)

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002602//PSUSA/10140/201407
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.2. Follow-up to PSUR procedures[4]

6.2.1. Agomelatine – **THYMANAX** (CAP), **VALDOXAN** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ingebjørg Buajordet (NO)

Administrative details:
Procedure number(s): EMEA/H/C/000915/LEG 025, EMEA/H/C/000916/MEA 025
Procedure scope: Follow up to PSUV/0021 and PSUV/0023 (PSUR#7) as adopted in September 2014
MAH(s): Les Laboratoires Servier, Servier (Ireland) Industries Ltd.
Documents:
For adoption: Updated PRAC Rapp AR

6.2.2. Epoetin beta – **NEORECORMON** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Valerie Strassmann (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000116/LEG 054
Procedure scope: MAH's response to PSUV/0084 (PSURs 19, 20 and 21) as adopted in September 2014
MAH(s): Roche Registration Ltd
Documents:
For adoption: Updated PRAC Rapp AR

6.2.3. Vernakalant – **BRINAVESS** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001215/LEG 021.1
Procedure scope: MAH's response to PSUV/0019 (PSUR #5 [PSU-008]) and LEG-021 as adopted in September 2014
MAH(s): Cardiome UK Limited
Documents:
For adoption: Updated PRAC Rapp AR

[4] Follow-up as per the conclusions of the previous PSUR procedure, assessed outside of the next PSUR procedure

7. Post-authorisation Safety Studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[5]

7.1.1. Hydroxyethyl starch (HES) (NAP)

- Evaluation of an imposed PASS protocol

Status: *for decision*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): PASS EMEA/H/N/PSP/J/0014.1
Procedure scope: Evaluation of a revised PASS protocol (drug utilisation study) to assess the effectiveness of the risk minimisation taken following the European Commission decision dated 19 December 2013 for the referral procedure EMEA/H/A-107I/1376
MAH(s): B. Braun Melsungen AG (Tetraspan, Venofundin), Fresenius Kabi Deutschland GmbH (Volulyte, Voluven Fresenius, Voluven, HyperHAES, HAES-steril), Serumwerk Bernburg AG (VitaHES, Vitafusal, Plasma Volume Redibag, PlasmaHES Redibag, Hesra, Hesra infuusioneste)
Documents:
For adoption: PRAC AR, Letter of endorsement/objection/notification that study is a clinical trial

7.1.2. Teicoplanin (NAP)

- Evaluation of an imposed PASS protocol

Status: *for decision*

Regulatory details:
PRAC Rapporteur: Valerie Strassmann (DE)

Administrative details:
Procedure number(s): EMEA/H/N/PSP/0011.2
Procedure scope: Evaluation of a revised protocol for a prospective observational cohort, non-comparative study describing the safety profile of the higher recommended teicoplanin loading dose of 12 mg/kg twice a day
MAH(s): Sanofi-Aventis (Targocid)
Documents:
For adoption: PRAC AR, Letter of endorsement/objection/notification that study is a clinical trial

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[6]

7.2.1. Aflibercept – ZALTRAP (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

[5] In accordance with Article 107n of Directive 2001/83/EC
[6] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

Administrative details:
Procedure number(s): EMEA/H/C/002532/MEA 003.2
Procedure scope: Revised PASS protocol for a drug utilisation study (DUS) to address potential for off-label use and particularly intravitreal off-label use (study AFLIBC06660)
MAH(s): Sanofi-Aventis Groupe
Documents:
For adoption: PRAC advice

7.2.2. Aripiprazole – ABILIFY MAINTENA (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002755/MEA/002.1
Procedure scope: Revised PASS protocol for a non-interventional, non-imposed post-authorisation safety study related to extrapyramidal symptoms in patients treated with Abilify Maintena: cohort study with a 2-year follow-up using European automated healthcare databases (study 15893N)
MAH(s): Otsuka Pharmaceutical Europe Ltd
Documents:
For adoption: PRAC advice

7.2.3. Delamanid – DELTYBA (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002552/MEA/002.1
Procedure scope: MAH's response to MEA-002 (revised PASS protocol for study 242-120402) adopted in September 2014
MAH(s): Otsuka Novel Products GmbH
Documents:
For adoption: PRAC advice

7.2.4. Flutemetamol (^{18}F)– VIZAMYL (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:

Procedure number(s): EMEA/H/C/002557/MEA 002
Procedure scope: Revised PASS protocol GE067-027 CPR, a post-authorisation study to assess the frequency of image classification errors in clinical practice in Europe
MAH(s): GE Healthcare Ltd
Documents:

For adoption: PRAC advice

7.2.5. Flutemetamol (^{18}F) – VIZAMYL (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002557/MEA 003
Procedure scope: PASS Protocol GE067-028: drug utilisation study as an additional pharmacovigilance activity to further characterise the safety concern
MAH(s): GE Healthcare Ltd
Documents:
For adoption: PRAC advice

7.2.6. Follitropin alfa – OVALEAP (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002608/MEA 002.1
Procedure scope: Revised PASS protocol XM17-WH-50005: non-interventional study of a prospective observational study to assess the safety of Ovaleap compared to Gonal-f in one treatment cycle with respect to the incidence rates of ovarian hyperstimulation syndrome (OHSS) in infertile women undergoing superovulation for assisted reproductive technologies (ART), as requested during the assessment of the marketing authorisation application for Ovaleap
MAH(s): Teva B.V.
Documents:
For adoption: PRAC advice

7.2.7. Ipilimumab – YERVOY (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002213/MEA 027.2
Procedure scope: Revised protocol for study CA184242ST (survey protocol for effectiveness assessment of the risk minimisation plan)
MAH(s): Bristol-Myers Squibb Pharma EEIG
Documents:
For adoption: PRAC advice

7.2.8. Mixture of polynuclear iron(III)-oxyhydroxide , sucrose and starches – VELPHORO (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002705/MEA 002
Procedure scope: PASS study VFMCRP-MEAF-PA21-01-EU: feasibility to evaluate the nature of diarrhoea with adjunct local gastrointestinal inflammatory markers in patients with chronic kidney disease on dialysis treated with Velphoro
MAH(s): Vifor Fresenius Medical Care Renal Pharma France
Documents:
For adoption: PRAC advice

7.2.9. Nilotinib – TASIGNA (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000798/MEA 038.2
Procedure scope: Request for the termination of the Tasigna and Glivec pregnancy registry for imatinib and nilotinib (CSTI571A2403)
MAH(s): Novartis Europharm Ltd
Documents:
For adoption: PRAC advice

7.2.10. Tocilizumab – ROACTEMRA (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000955/MEA 045.2
Procedure scope: Revised PASS protocol for a UK BSR rheumatoid arthritis registry of tocilizumab treated patients and prospective surveillance study for adverse events
MAH(s): Roche Registration Limited
Documents:
For adoption: PRAC advice

7.3. Results of PASS imposed in the marketing authorisation(s)[7]

None

[7] In accordance with Article 107p-q of Directive 2001/83/EC

7.4. Results of PASS non-imposed in the marketing authorisation(s)[8]

7.4.1. Aliskiren – RASILEZ (CAP)
aliskiren, amlodipine – RASILAMLO (CAP)
aliskiren, hydrochlorothiazide - RASILEZ HCT (CAP)

- Evaluation of PASS results

Status: *for discussion and agreement of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Carmela Macchiarulo (IT)

Administrative details:
Procedure number(s): EMEA/H/C/000780/WS0581/0093, EMEA/H/C/002073/WS0581/0094, EMEA/H/C/000964/WS0581/0063 (without RMP)
Procedure scope: Submission of the final study report for the non- interventional study CSPP100A2414: cohort study to assess various safety outcomes in aliskiren initiators using US claims data
MAH(s): Novartis Europharm Ltd
Documents:
For adoption: PRAC AR

7.4.2. Bivalirudin – ANGIOX (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000562/II/0058 (without RMP)
Procedure scope: Submission of the study report for the study 'exposure and adverse event assessment (EAEA) for Angiomax protocol TMC-BIV-07-01 bivalirudin (Angiomax) as a procedural anticoagulant in the paediatric population undergoing intravascular procedures for congenital heart disease''
MAH(s): The Medicines Company UK Ltd.
Documents:
For adoption: PRAC AR

7.4.3. Elvitegravir – VITEKTA (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002577/II/0011 (with RMP)
Procedure scope: Submission of the final clinical study report for study GS-US-183-1004, a phase 1, multiple-dose study to evaluate the pharmacokinetics of cobicistat-boosted elvitegravir (EVG) in subjects with decreased UGT1A1 activity (study included as a category 3 additional pharmacovigilance

[8] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

study/activity in the RMP), in order to address post-authorisation measure MEA 006. A revised RMP version 1.0 has been provided as part of the application
MAH(s): Gilead Sciences International Ltd
Documents:
For adoption: PRAC AR

7.4.4. Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil – STRIBILD (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002574/II/0039 (without RMP)
Procedure scope: Submission of the final study report for study GS-US-183-1004, phase I, multiple-dose study to evaluate the pharmacokinetics of cobicistat-boosted elvitegravir in subjects with decreased UGT1A1 activity
MAH(s): Gilead Sciences International Ltd
Documents:
For adoption: PRAC AR

7.4.5. Etanercept – ENBREL (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000262/II/0176 (without RMP)
Procedure scope: Submission of the final report for study B1801130 as listed in RMP Part III
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC AR

7.4.6. Etanercept – ENBREL (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000262/II/0177
Procedure scope: Submission of the final report for study B1801130 as listed in RMP Part III
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC AR

7.4.7. Ivacaftor – KALYDECO (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

Administrative details:
Procedure number(s): EMEA/H/C/002494/II/0035 (with RMP)
Procedure scope: Submission of the final study VX08-770-105 clinical study report (CSR) to fulfil the post-authorisation measure (PAM) ANX 002
MAH(s): Vertex Pharmaceuticals (U.K.) Ltd
Documents:
For adoption: PRAC AR

7.4.8. Lamivudine, zidovudine – COMBIVIR (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000190/II/0078 (with RMP)
Procedure scope: Variation to fulfil the obligations to provide the final study report for an observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescent using the EPPICC data as mentioned in version 4 of Combivir EU RMP
MAH(s): ViiV Healthcare UK Limited
Documents:
For adoption: PRAC AR

7.4.9. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) – PREVENAR 13 (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/001104/II/0116 (without RMP)
Procedure scope: Submission of a final report for post-authorisation observational safety study of 13-valent pneumococcal conjugate vaccine (13vPnC) administered in routine use to infants and toddlers
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC AR

7.4.10. Tolvaptan – SAMSCA (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000980/II/0020 (without RMP)
Procedure scope: Submission of the final study report for Samsca post-authorisation safety study (FUM 004)
MAH(s): Otsuka Pharmaceutical Europe Ltd
Documents:
For adoption: PRAC AR

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variations regulation[9]

7.5.1. Efavirenz – SUSTIVA (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

Administrative details:
Procedure number(s): EMEA/H/C/000249/MEA 079.1
Procedure scope: Annual report on malignant events and MAH's response to MEA-079 (annual periodic update report for malignant events) as adopted in September 2014
MAH(s): Bristol-Myers Squibb Pharma EEIG
Documents:
For adoption: PRAC advice

7.5.2. Efavirenz, emtricitabine, tenofovir disoproxil – ATRIPLA (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000797/MEA 039.1
Procedure scope: MAH's response to MEA-039 (annual periodic update report for malignant events) as adopted in September 2014
MAH(s): Bristol-Myers Squibb and Gilead Sciences Ltd.
Documents:
For adoption: PRAC advice

7.5.3. Emtricitabine, tenofovir disoproxil – TRUVADA (CAP)

- Evaluation of interim PASS results

[9] In line with the revised variations regulation for any submission before 4 August 2013

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000594/MEA 041.2
Procedure scope: MAH's response to MEA-041.1 (week 144 interim report for clinical study GS-US-236-0103] as adopted in September 2014
MAH(s): Gilead Sciences International Ltd
Documents:
For adoption: PRAC advice

7.5.4. Filgrastim – **BIOGRASTIM** (CAP), **RATIOGRASTIM** (CAP), **TEVAGRASTIM** (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Kirsti Villikka (FI)

Administrative details:
Procedure number(s): EMEA/H/C/000826/MEA 019.1, EMEA/H/C/000825/MEA 019.1, EMEA/H/C/000827/MEA 019.1
Procedure scope: Second annual report consisting of adverse drug reaction data from all sources including spontaneous reports and reports from the severe chronic neutropenia international registry (SCNIR)
MAH(s): AbZ Pharma GmbH, Ratiopharm GmbH, Teva GmbH
Documents:
For adoption: PRAC advice

7.5.5. Infliximab – **INFLECTRA** (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002778/MEA 019
Procedure scope: Annual report of adverse events of special interest (tuberculosis and other serious infections) with the relevant PSUR submissions. It summarises the safety data received by the MAH, from worldwide interventional, registries and observational clinical trials, between 10 September 2013 and 10 September 2014
MAH(s): Hospira UK Limited
Documents:
For adoption: PRAC advice

7.5.6. Influenza vaccine (split viron, inactivated) – **IDFLU** (CAP), **INTANZA** (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000966/MEA 032, EMEA/H/C/000957/MEA 032
Procedure scope: Enhanced safety surveillance for NH 2014-2015 Campaign (intermediate results interventional studies/GID47 final report)
MAH(s): Sanofi Pasteur, Sanofi Pasteur MSD SNC
Documents:
For adoption: PRAC advice

7.5.7. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) – OPTAFLU (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/000758/LEG 050
Procedure scope: Report on an enhanced safety surveillance following the annual strain update as laid down in the interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU
MAH(s): Novartis Vaccines and Diagnostics GmbH
Documents:
For adoption: PRAC advice

7.5.8. Mannitol – BRONCHITOL (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001252/ANX 002.4
Procedure scope: Fourth interim analysis of the cystic fibrosis (CF) study
MAH(s): Pharmaxis Pharmaceuticals Limited
Documents:
For adoption: PRAC advice

7.5.9. Oseltamivir – TAMIFLU (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Kirsti Villikka (FI)

Administrative details:
Procedure number(s): EMEA/H/C/000402/LEG 087.2

Procedure scope: Annual review on the pregnancy data
MAH(s): Roche Registration
Documents:
For adoption: PRAC advice

7.5.10. Raltegravir – ISENTRESS (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000860/MEA 048.4
Procedure scope: Fourth (and final) annual report for a post-authorisation safety study in a US managed care network
MAH(s): Merck Sharp & Dohme Limited
Documents:
For adoption: PRAC advice

7.5.11. Tenofovir disoproxil – VIREAD (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000419/MEA 268.2
Procedure scope: MAH's response to MEA-268.1 (week 144 interim report for clinical study GS-US-236-0103) as adopted in October 2014
MAH(s): Gilead Sciences International Ltd
Documents:
For adoption: PRAC advice

7.5.12. Ticagrelor – BRILIQUE (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001241/MEA 008.4
Procedure scope: Fourth annual progress report on a drug utilisation study D5130N00010A: pharmacoepidemiological study to examine patient characteristics, drug utilization pattern and crude incidence rates of selected outcomes in new users of ticagrelor, clopidogrel and prasugrel in national Swedish registries
MAH(s): AstraZeneca AB
Documents:
For adoption: PRAC advice

8. Renewals of the marketing authorisation, conditional renewals and annual reassessments

8.1.1. Anagrelide – XAGRID (CAP)

- PRAC consultation on an annual reassessment of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Arnaud Batz (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000480/S/0064 (without RMP)
MAH(s): Shire Pharmaceutical Contracts Ltd
Documents:
For adoption: PRAC advice

8.1.2. Histamine dihydrochloride – CEPLENE (CAP)

- PRAC consultation on an annual reassessment of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Almath Spooner (IE)

Administrative details:
Procedure number(s): EMEA/H/C/000796/S/0022 (without RMP)
MAH(s): Meda AB
Documents:
For adoption: PRAC advice

8.1.3. Trabectedin – YONDELIS (CAP)

- PRAC consultation on an annual reassessment of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Torbjorn Callreus (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000773/S/0042 (without RMP)
MAH(s): Pharma Mar, S.A.
Documents:
For adoption: PRAC advice

See under 5.2

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. On-going or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation (MA)

10.1.1. Albiglutide – EPERZAN (CAP)

- PRAC consultation on a safety-related variation, upon CHMP request

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002735/II/009
Procedure scope: Update of SmPC section 4.8 with information on appendicitis/pancreatitis. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to correct some information in SmPC sections 5.1 and 6.6, Annex III.A and package leaflet
MAH(s): GlaxoSmithKline Trading Services
Documents:
For adoption: PRAC advice

10.1.2. Ambrisentan – VOLIBRIS (CAP)

- PRAC consultation on a safety-related variation, upon CHMP request

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000389/0039
Procedure scope: Update of SmPC section 4.4 in relation to the current recommendations for liver function and SmPC section 5.1 with data on aminotransferase abnormalities from an analysis of the clinical study report (CSR) for PASS 'AMB110094 (VOLT)'. The current 'healthcare professional information' in Annex II has been updated accordingly as well as the package leaflet and RMP (version 6)
MAH(s): Glaxo Group Ltd
Documents:
For adoption: PRAC advice

10.2. Timing and message content in relation to MS safety announcements

None

10.3. Other requests

10.3.1. Dabigatran – **PRADAXA** (CAP)

- PRAC consultation on a post-authorisation measure, upon CHMP request

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Torbjorn Callreus (DK)

Administrative details:
Procedure number(s): EMA/H/C/000829/LEG/043.1
Procedure scope: MAH's response to LEG-043 as adopted by CHMP on 29 September 2014, pertaining to four publications form the BMJ
MAH(s): Boehringer Ingelheim International GmbH
Documents:
For adoption: PRAC advice

10.3.2. Epoetins:

Darbepoetin alfa – ARANESP (CAP);
Epoetin alfa – ABSEAMED (CAP), **BINOCRIT** (CAP), **EPOETIN ALFA HEXAL** (CAP);
Epoetin beta – MIRCERA (CAP), **NEORECORMON** (CAP);
Epoetin theta – BIOPOIN (CAP), **EPORATIO** (CAP);
Epoetin zeta – RETACRIT (CAP), **SILAPO** (CAP)

- PRAC consultation on post-authorisation measures, upon CHMP request

Status: *for discussion*

Regulatory details:

PRAC Rapporteur (overall): Valerie Strassmann (DE)
PRAC Co-Rapporteurs: Arnaud Batz (FR), Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000332/LEG 083.4 (Aranesp), EMEA/H/C/000727/LEG 023.4 (Abseamed), EMEA/H/C/000725/LEG 022.4 (Binocrit), EMEA/H/C/000726/LEG 023.4 (epoetin Alfa Hexal), EMEA/H/C/000739 LEG 032.4 (Mircera), EMEA/H/C/000116/LEG 049.4 (NeoRecormon), EMEA/H/C/001036/LEG 019.4 (Biopoin), EMEA/H/C/001033/LEG 019.4 (Eporatio), EMEA/H/C/000872/LEG 036.4 (Retacrit), EMEA/H/C/000760/LEG 035.4 (Silapo)
Scope: Erythropoiesis-stimulating agents (ESA): Evaluation of the outcome of statistical analysis of clinical trial data in chronic kidney disease (CKD) patients on dialysis/not on dialysis (treatment of anaemia)
MAH(s): Amgen Europe B.V. (Aranesp), Medice Arzneimittel Pütter GmbH & Co. KG (Abseamed), Sandoz GmbH (Binocrit), Hexal AG (Epoetin Alfa Hexal), Roche Registration Ltd (Mircera, NeoRecormon), CT Arzneimittel GmbH (Biopoin), Ratiopharm GmbH (Eporatio)
Documents:
For adoption: PRAC advice

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Renewals of the marketing authorisation

None

11.3. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

None

12.2. Pharmacovigilance audits and inspections

12.2.1. Pharmacovigilance Systems and their Quality Systems

None

12.2.2. Pharmacovigilance inspections

None

12.2.3. Pharmacovigilance audits

12.2.3.1. Pharmacovigilance Audit Facilitation Group (PAFG)

- Nomination of PRAC representatives

***Status**: for discussion*

12.3. Periodic Safety Update Reports & Union Reference Date (EURD) List

12.3.1. Periodic Safety Update Reports

- PSUR Single Assessment (PSUSA) procedure numbers

***Status:** for discussion*

12.3.2. PSURs repository

- PSURs repository implementation plan: update

Status: *for discussion*

12.3.3. Union Reference Date List

- Consultation on the draft list, version February 2015
- Feedback from the Granularity and Periodicity Advisory Group (GPAG)

Status*: for discussion and agreement of the list*

Documents:
For adoption: Revised EURD list

12.4. Signal Management

12.4.1. Signal Management

- Feedback from Signal Management Review Technical (SMART) Working Group

Status*: for information*

12.5. Adverse Drug Reactions reporting and additional monitoring

12.5.1. Management and reporting of adverse reactions to medicinal products

12.5.1.1. Collection of off-label information without suspected adverse reaction

- EMA questions and answers document on recording and reporting of off-label use

Status: *for discussion*

12.5.1.2. Monitoring of medical literature

- Detailed guide for the monitoring of medical literature and the entry of relevant information into EudraVigilance database

Status: *for discussion*

Documents:
For discussion: Draft detailed guide

12.5.2. Additional monitoring

12.5.2.1. List of products under additional monitoring

- Consultation on the draft list, version February 2015

Status: *for information*

Documents:
For discussion: Revised additional monitoring list

- Guidance on the maintenance of the list of products under additional monitoring

Status: *for agreement*

Documents:
For agreement: Draft guidance document

12.6. EudraVigilance database

12.6.1. Activities related to the confirmation of full functionality

None

12.7. Risk Management Plans and effectiveness of risk minimisations

12.7.1. Risk Management Systems

None

12.7.2. Tools, Educational Materials and effectiveness measurement for risk minimisations

- Guideline on good pharmacovigilance practices (GVP) Module XVI on educational materials

Status: *for discussion*

Documents:
For discussion: Draft detailed guide

12.8. Post-authorisation Safety Studies

12.8.1. Post-authorisation Safety Studies

- Non-imposed PASS protocols – proposal for a revised process

Status: *for discussion*

12.9. Community procedures

12.9.1. Referral procedures for safety reasons

None

12.10. Renewals, conditional renewals, annual reassessments

None

12.11. Risk communication and transparency

12.11.1. Public participation in pharmacovigilance

None

12.11.2. Safety communication

None

12.12. Continuous pharmacovigilance

12.12.1. Incident Management

None

12.13. Interaction with EMA Committees and Working Parties

12.13.1. Committees

None

12.13.2. Blood Products Working Party (BPWP)

- Guideline on clinical investigation of recombinant and human plasma-derived factor IX products

Status: *for discussion*

Documents:
For discussion: Revised draft guideline

12.13.3. Vaccine Working Party (VWP)

- Seasonal influenza vaccines: Manufacturers' proposal for passive enhanced safety surveillance for the 2015-1016 season

Status: *for discussion*

12.13.4. Scientific Advisory Group (SAG) Oncology

- Bisphosphonates, denosumab: effectiveness of risk minimisation measures: consultation of the SAG oncology on the risk of osteonecrosis of the jaw (ONJ) and action plan for implementation

Status: *for discussion*

12.14. Interaction within the EU regulatory network

None

12.15. Contacts of the PRAC with external parties and interaction of the EMA with interested parties

12.15.1. Guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

None

12.15.2. International Society for Pharmaceutical Engineering (ISPE)

- Analysis of patient and healthcare professional input in EMA oral contraceptive communication, following the symposium, October 2014

Status: *for discussion*

13. Any other business

13.1. Medication errors

- Guidance on medication errors following PRAC and Patient Safety and Quality of Care Working Group (PSQCWG)'s consultation

***Status**: for discussion*

Documents:
For discussion: Revised draft guidance

13.2. Pharmacovigilance programme and revised implementation governance

***Status:** for discussion*